- Types of Eczema
- Eczema in Children
- Living Well
- Eczema Products
- Get Involved
- For Medical Professionals
Dermatologists discuss the potential efficacy of prescribing an opioid antagonist to address the problem of itch in atopic dermatitis.
A new, nonsteroidal topical cream for AD called Jakafi (ruxolitinib) may soon hit pharmacy shelves.
Does atopic dermatitis behave differently based on a person’s skin tone? Researchers at the University of Amsterdam are trying to find out.
Off-label use of biologic treatments for atopic dermatitis may double the risk for serious infection compared to systemic treatments, researchers found.
A topical treatment containing a common “healthy” skin bacterium was found to reduce AD severity in adults and kids in an early-phase clinical trial.
Honey, L-histidine, East Indian Sandalwood oil, vitamin E and melatonin are among the latest complementary and alternative treatments for eczema undergoing clinical research.
Atopic dermatitis is more than just financial burden on households. It has social, economic, academic and occupational repercussions as well, studies show.
Dupixent, a biologic drug for moderate to severe AD, may soon be available to patients aged 12 to 18 if the treatment continues its success rate in adolescent clinical trials.
Now that we’re in the “Era of Eczema,” it’s never been easier for patients to help researchers develop better treatments for atopic dermatitis.
Prevention strategies can help reduce the risk of cardiovascular disease among patients with severe or predominately active AD, including awareness of and screening for conventional cardiovascular risk factors.